Search
Influenza B virus B/Phuket/3073/2013 antigen (propiolactone inactivated)
go.drugbank.com/drugs/DB10602ApprovedWithdrawnA seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposin...
Mixtures: Medical Provider Single Use EZ Flu Shot Fluvirin 2015-2016Influenza A virus A/Texas/50/2012 X-223A (H3N2) antigen (MDCK cell derived, propiolactone inactivated)
go.drugbank.com/drugs/DB10999ApprovedInvestigationalWithdrawnA seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposin...
Mixtures: Medical Provider Single Use EZ Flu Shot Flucelvax 2014-2015 KitDermatophagoides farinae
go.drugbank.com/drugs/DB10400ApprovedInvestigationalDermatophagoides farinae extracts are sterile solutions used for intradermal testing or subcutaneous immunotherapy. This combination is approved for as a year-round, once-a-day tablet that's dissolved under the tongue as a treatment for ...
Mixtures: Allergenic Extract Mixture Of Standardized Mites (5,000 Au/ml), Allergenic Extract Mixture Of Standardized Mites (15,000 Au/ml)Products: Allergenic Extract Standardized Mite Df (10,000 Au/ml), Allergenic Extract Standardized Mite Df (30,000 Au/ml)Fursultiamine
go.drugbank.com/drugs/DB08966ApprovedCompound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
Mixtures: ALINAMIN EX PLUSBenzatropine
go.drugbank.com/drugs/DB00245ApprovedInvestigational[A37914] Benztropine was developed by USL Pharma and officially approved by the FDA on 1996.[L5500]
Lindane
go.drugbank.com/drugs/DB00431ApprovedWithdrawnIn Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical
Mavorixafor
go.drugbank.com/drugs/DB05501ApprovedInvestigational[L50642] It was first approved by the FDA on April 30, 2024, for the treatment of warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome, a genetic immunodeficiency disorder characterized
Parathyroid hormone
go.drugbank.com/drugs/DB05829ApprovedInvestigationalFood and Drug Administration (FDA).
Tapinarof
go.drugbank.com/drugs/DB06083ApprovedInvestigational[A248790] Tapinarof received initial approval from the FDA in 2022.[L41845]
Pibrentasvir
go.drugbank.com/drugs/DB13878ApprovedInvestigationalthe emergence of amino acid substitutions at known NS5A inhibitor resistance-associated positions in HCV genotype 1a, 2a or 3a replicons led to reduced susceptibility and resistance to pibrentasvir [FDA … This fixed-dose combination therapy was FDA-approved in August 2017 to treat adults with chronic hepatitis C virus (HCV) genotypes 1-6 without cirrhosis (liver disease) or with mild cirrhosis, including